Optimization and validation of a biomarker panel for risk stratification in Barrett's esophagus
用于巴雷特食管风险分层的生物标志物组的优化和验证
基本信息
- 批准号:10584271
- 负责人:
- 金额:$ 64.4万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-12-28 至 2027-11-30
- 项目状态:未结题
- 来源:
- 关键词:AmericanAneuploidyAreaBarrett EsophagusBenignBile RefluxBiological AssayBiological MarkersBiometryBiopsyCase/Control StudiesChronicClinicalClinical ManagementCollaborationsCollectionComputational BiologyComputational TechniqueCoupledCredentialingDNA Sequence AlterationDetectionDevelopmentDevicesDiagnosisDiseaseDysplasiaEarly DiagnosisEndoscopic BiopsyEndoscopyEpitheliumEsophageal AdenocarcinomaEsophageal TissueEsophagusEvaluationFunctional disorderFundingGastroenterologistGastroenterologyGastroesophageal reflux diseaseGenomeGenomicsGoalsHeadHigh PrevalenceHistologicIncidenceInstitutionIntestinesLeftLesionMalignant NeoplasmsMalignant neoplasm of esophagusMethylationModelingMutationMutation DetectionOutcomePathologyPatientsPersonsPloidiesPositioning AttributePrecancerous ConditionsProceduresProcessProgress ReportsProspective cohortPublishingRecommendationResearchResourcesRiskSamplingSideStratificationStructureTP53 geneTalentsTestingTimeTissue BanksTissue SampleTissuesValidationadvanced diseasebiomarker identificationbiomarker panelcancer genomicsclinical implementationclinically relevantclinically significantcohortcostcost effectivedisorder riskepigenomicsgenomic biomarkerhigh riskimprovedinnovationmethylation biomarkernovelnovel therapeuticspatient populationpatient stratificationpredictive markerpremalignantpreventprogression riskresponserisk stratificationscreeningsubclonal heterogeneitysurveillance strategytargeted sequencingtool
项目摘要
PROJECT SUMMARY: Intestinalization of the esophagus, termed Barrett’s esophagus (BE), is thought to
develop in response to chronic acid and bile reflux and carries great clinical significance because it is the
precursor to esophageal adenocarcinoma (EAC). The incidence of BE is quite high, estimated to be found in at
least 1:100 people. While relatively few with BE progress to cancer there is great importance to being able to
detect and treat those at risk of progression as EAC is an aggressive cancer with potential for early spread.
Efforts to screen for high-risk disease in those with BE have, to date, not been very successful. Therefore,
there is profound need to define the process by which BE progresses into EAC, to develop biomarkers to
diagnose early progression and assess progression risk in BE tissues as well as to develop novel therapies for
treatment. The objective of this R01 proposal is to investigate the ability of biomarkers to identify BE patients at
high risk of progression. Using results from two externally funded genomic studies in non-dysplastic BE
(NDBE) and BE with low-grade dysplasia (LGD) and previously published results, we will compare biomarkers
and determine an optimized combination for risk stratification in two prospective cohorts including patients with
NDBE or LGD. We will then validate our risk stratification assay in an independent US cohort. Finally, we will
compare our genomic biomarker panel results in paired biopsy and brush samples. A unique collaboration
between the PI Dr. Stachler, expert gastroenterologist (Dr. J Bergman), a talented computational biologist (Dr.
CZ Zhang), and an expert biostatistician (Dr. K Zwinderman) along with key collaborators allows a truly
innovated study to be performed. This will be accomplished using an unprecedented collection of clinically
derived samples, a highly optimized targeted sequencing panel, and novel computational approaches that
allow a wide array of information to be determined in a cost effective, clinically relevant manor.
Aim 1: Identify a set of genomic biomarkers highly predictive of progression in biopsies from a
prospective cohort of patients diagnosed with NDBE and LGD and assess whether the addition of
methylation-based biomarkers improves stratification. For clinical implementation all biomarkers should be
compared head to head in order to determine an optimized combination of biomarkers for risk stratification.
Aim 2: Validate the risk stratification assay in a multi-institutional cohort of patients with a baseline
diagnosis of NDBE or LGD. For clinical implementation, it is vital to validate any risk stratification assay on
completely independent cohorts looking at clinically relevant time points.
Aim 3: Determine if brush-based sampling devices improve biomarker detection over standard
endoscopic biopsies. Broad sampling of the BE epithelium may allow for increased rates of detection for
genomic or methylation biomarkers, therefore we will determine if samples from a brushed based device can
better risk stratify patients compared to standard biopsies.
项目总结:食管的肠化,称为巴雷特食管(BE),被认为是
慢性酸和胆汁反流的反应,并进行重大的临床意义,因为它是
食管腺癌(EAC)的前体。BE的发病率相当高,估计在
1:100人。虽然相对较少的BE进展为癌症,但能够
检测和治疗有进展风险的患者,因为EAC是一种具有早期扩散潜力的侵袭性癌症。
迄今为止,在BE患者中筛查高危疾病的努力并不十分成功。因此,我们认为,
我们迫切需要确定BE进展为EAC的过程,开发生物标志物,
诊断早期进展并评估BE组织中的进展风险,以及开发新的治疗方法,
治疗本R01提案的目的是研究生物标志物识别BE患者的能力,
进展的高风险。使用两项外部资助的非异型增生BE基因组研究的结果
(NDBE)和BE伴低度异型增生(LGD)和以前发表的结果,我们将比较生物标志物
并在两个前瞻性队列中确定风险分层的最佳组合,
NDBE或LGD。然后,我们将在一个独立的美国队列中验证我们的风险分层分析。最后我们将
比较配对活检和刷检样本中的基因组生物标志物面板结果。的独特合作
之间的PI博士Stachler,专家胃肠病学家(博士J伯格曼),一个有才华的计算生物学家(博士。
CZ Zhang)和生物统计学专家(K Zwinderman博士)沿着主要合作者,
进行创新研究。这将通过前所未有的临床收集来实现。
衍生的样品,高度优化的靶向测序面板,和新的计算方法,
允许以成本有效的、临床相关的方式确定广泛的信息。
目的1:确定一组高度预测来自非小细胞肺癌的活检进展的基因组生物标志物。
诊断为NDBE和LGD的患者的前瞻性队列,并评估是否添加
基于甲基化的生物标志物改善了分层。对于临床实施,所有生物标志物应
头对头比较,以确定用于风险分层的生物标志物的优化组合。
目的2:在多机构队列患者中进行风险分层分析,
诊断NDBE或LGD。对于临床实施,验证任何风险分层分析至关重要,
观察临床相关时间点的完全独立队列。
目标3:确定基于刷子的采样设备是否能提高生物标志物检测的标准
内窥镜活检BE上皮细胞的广泛采样可以提高BE的检出率。
基因组或甲基化生物标志物,因此,我们将确定来自刷基器械的样本是否可以
与标准活检相比,更好地对患者进行风险分层。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Matthew D Stachler其他文献
Matthew D Stachler的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Matthew D Stachler', 18)}}的其他基金
Early TP53 Mutations and Genomic Doubling as a Novel Path for Barrett's Esophagus Progression
早期 TP53 突变和基因组加倍是巴雷特食管进展的新途径
- 批准号:
9086012 - 财政年份:2016
- 资助金额:
$ 64.4万 - 项目类别:
Early TP53 Mutations and Genomic Doubling as a Novel Path for Barrett's Esophagus Progression
早期 TP53 突变和基因组加倍是巴雷特食管进展的新途径
- 批准号:
9666941 - 财政年份:2016
- 资助金额:
$ 64.4万 - 项目类别:
Early TP53 Mutations and Genomic Doubling as a Novel Path for Barrett's Esophagus Progression
早期 TP53 突变和基因组加倍是巴雷特食管进展的新途径
- 批准号:
9262219 - 财政年份:2016
- 资助金额:
$ 64.4万 - 项目类别:
Early TP53 Mutations and Genomic Doubling as a Novel Path for Barrett's Esophagus Progression
早期 TP53 突变和基因组加倍是巴雷特食管进展的新途径
- 批准号:
9929248 - 财政年份:2016
- 资助金额:
$ 64.4万 - 项目类别:
Early TP53 Mutations and Genomic Doubling as a Novel Path for Barrett's Esophagus Progression
早期 TP53 突变和基因组加倍是巴雷特食管进展的新途径
- 批准号:
10380456 - 财政年份:2016
- 资助金额:
$ 64.4万 - 项目类别:
相似海外基金
Elucidating the effects of extra chromosome elimination in mosaic aneuploidy syndromes: Pallister-Killian syndrome as a model
阐明额外染色体消除对嵌合非整倍体综合征的影响:以 Pallister-Killian 综合征为模型
- 批准号:
10887038 - 财政年份:2023
- 资助金额:
$ 64.4万 - 项目类别:
Characterization of aneuploidy, cell fate and mosaicism in early development
早期发育中非整倍性、细胞命运和嵌合体的表征
- 批准号:
10877239 - 财政年份:2023
- 资助金额:
$ 64.4万 - 项目类别:
The impact of aneuploidy on early human development
非整倍体对人类早期发育的影响
- 批准号:
MR/X007979/1 - 财政年份:2023
- 资助金额:
$ 64.4万 - 项目类别:
Research Grant
Understanding how aneuploidy disrupts quiescence in the model eukaryote Saccharomyces cerevisiae
了解非整倍体如何破坏模型真核生物酿酒酵母的静止状态
- 批准号:
10735074 - 财政年份:2023
- 资助金额:
$ 64.4万 - 项目类别:
Preventing Age-Associated Oocyte Aneuploidy: Mechanisms Behind the Drosophila melanogaster Centromere Effect
预防与年龄相关的卵母细胞非整倍性:果蝇着丝粒效应背后的机制
- 批准号:
10538074 - 财政年份:2022
- 资助金额:
$ 64.4万 - 项目类别:
Functional evaluation of kinesin gene variants associated with female subfertility and egg aneuploidy.
与女性生育力低下和卵子非整倍性相关的驱动蛋白基因变异的功能评估。
- 批准号:
10537275 - 财政年份:2022
- 资助金额:
$ 64.4万 - 项目类别:
Using CRISPR screening to uncover aneuploidy-specific genetic dependencies
使用 CRISPR 筛选揭示非整倍体特异性遗传依赖性
- 批准号:
10661533 - 财政年份:2022
- 资助金额:
$ 64.4万 - 项目类别:
Comparative Analysis of Aneuploidy and Cellular Fragmentation Dynamics in Mammalian Embryos
哺乳动物胚胎非整倍性和细胞破碎动力学的比较分析
- 批准号:
10366610 - 财政年份:2022
- 资助金额:
$ 64.4万 - 项目类别:
FASEB SRC: The Consequences of Aneuploidy: Honoring the Contributions of Angelika Amon
FASEB SRC:非整倍体的后果:纪念 Angelika Amon 的贡献
- 批准号:
10467260 - 财政年份:2022
- 资助金额:
$ 64.4万 - 项目类别: